

## **Provisional 2027 EPHMRA ATC Developments**

The following new class structures were voted on by EPHMRA/Intellus in June 2026 and agreed in principle. These structures will now be used in the next part of the development process which is the detailed refinement of the rules.

Please note that these new class structures are provisional at this time. The 2027 codes, descriptions and Guideline text will be finalised and published by the Committee at the end of 2026. The new structures then come into effect from the beginning of 2027.

### **L class restructure**

The proposal is to

- 1) Create a new, dedicated 1<sup>st</sup> level class exclusively for immunological agents and,
- 2) Promote existing 3<sup>rd</sup> level antineoplastic classes to the 2<sup>nd</sup> level. The current L2 class would be unchanged.

This proposal provides a distinction between antineoplastics and immunomodulators and will create capacity in the classification system, allowing it to adapt to future developments, particularly in the antineoplastic area.

The proposed structure is as follows:

|          |                                          |
|----------|------------------------------------------|
| <b>L</b> | <b>ANTINEOPLASTICS</b>                   |
| L2       | CYTOSTATIC HORMONE THERAPY               |
| L5       | ALKYLATING ANTINEOPLASTICS               |
| L6       | ANTIMETABOLITE ANTINEOPLASTICS           |
| L7       | PLANT-BASED ANTINEOPLASTICS              |
| L8       | ANTIBIOTIC ANTINEOPLASTICS               |
| L9       | PLATINUM ANTINEOPLASTICS                 |
| L10      | MONOCLONAL ANTIBODY ANTINEOPLASTICS      |
| L11      | PROTEIN KINASE INHIBITOR ANTINEOPLASTICS |
| L12      | PROTEASOME INHIBITOR ANTINEOPLASTICS     |
| L13      | LIDOMIDE ANTINEOPLASTICS                 |
| L14      | PARP INHIBITOR ANTINEOPLASTICS           |
| L99      | ANTINEOPLASTICS, OTHER                   |
| <b>F</b> | <b>IMMUNOMODULATORS</b>                  |
| F1       | IMMUNOSTIMULATING AGENTS                 |
| F2       | IMMUNOSUPPRESSANTS                       |

Lower-level classification remains consistent with the new levels immediately above, for example:

|            |      |                                           |
|------------|------|-------------------------------------------|
| “current”  | L1G  | MONOCLONAL ANTIBODY ANTINEOPLASTICS       |
|            | L1G1 | Monoclonal antibody antineoplastics, CD20 |
| “proposed” | L10  | MONOCLONAL ANTIBODY ANTINEOPLASTICS       |
|            | L10A | MONOCLONAL ANTIBODY ANTINEOPLASTICS, CD20 |

For further information, please refer to the document of *Proposed changes to the current L class: Oncology/Immunology split*, available on the EPHMRA Anatomical Classification page  
<https://www.ephmra.org/anatomical-classification>